GO
Loading...

Novartis AG

More

  • U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range. The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.

  • LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • UPDATE 2-GSK warns on profits as weak lung drug sales hit Wednesday, 23 Jul 2014 | 9:12 AM ET

    LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • LONDON, July 23- GlaxoSmithKline cut its 2014 outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • Weak lung drug sales and strong pound hit GlaxoSmithKline Wednesday, 23 Jul 2014 | 7:11 AM ET

    LONDON, July 23- GlaxoSmithKline's sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • LONDON, July 22- European shares bounced back on Tuesday on some strong earnings reports and after signs of cooperation between Russia and other nations in investigating the shooting down of a Malaysian airliner over Ukraine.

  • European shares bounce back as Ukraine tension ease Tuesday, 22 Jul 2014 | 11:25 AM ET

    LONDON, July 22- European shares rose on Tuesday on some strong earnings reports and signs of improved cooperation from Ukraine's pro-Russian rebels over the Malaysian Airlines plane shot down four days ago.

  • LONDON/ MUMBAI, July 22- Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline, five sources familiar with the matter said.

  • *ARM Holdings surges after strong results. LONDON, July 22- European equities bounced back on Tuesday partly in response to signs of improved cooperation from Ukraine's pro-Russian rebels who have agreed to hand over the black boxes from the Malaysian plane downed in Ukraine last week.

  • CHICAGO, July 21- All too often, I see investors heading in the wrong direction en masse. The Energy SPDR, which charges 0.16 percent for annual management expenses and holds Exxon Mobil Corp, Chevron Corp and Schlumberger NV, has climbed 22 percent in the past 12 months, with nearly one-third of that gain coming in the three months through July 18.

  • July 18- Catalent Inc, controlled by Blackstone Group LP, said it expects its initial public offering to be priced between $19 and $22 per share, valuing the company at about $2.57 billion at the top end. The company's major customers include Pfizer Inc, Johnson& Johnson, GlaxoSmithKline Plc, Merck& Co Inc and Novartis AG.

  • *Earnings pin back Sandvik, SGS. EDINBURGH, July 17- European stocks fell on Thursday, with appetite for equities dented by new Western sanctions on Russia and a mixed earnings picture. Stocks with high exposure to Russia were among the top fallers after the European Union and the United States increased sanctions on the country.

  • ZURICH, July 17- Swiss drugmaker Novartis posted a quarterly rise in sales that missed expectations and said it would focus on eking out gradual cost savings to boost margins as it prepares a radical business overhaul.

  • EDINBURGH, July 17- European stocks fell on Thursday, weighed down by mixed earnings reports after posting their best gains in three months in the previous session, while new Western sanctions on Russia also hit stocks exposed to the country.

  • Novartis cites momentum in 3 percent profit rise Thursday, 17 Jul 2014 | 2:07 AM ET

    GENEVA— Swiss pharmaceutical company Novartis AG posted a 3 percent rise in second-quarter profits Thursday, reflecting what it described as solid growth and an increased focus on core products.

  • Business events scheduled for Thursday Wednesday, 16 Jul 2014 | 1:58 PM ET

    WASHINGTON— Commerce Department releases housing starts for June, 8:30 a.m.. WASHINGTON— Labor Department releases weekly jobless claims, 8:30 a.m.. WASHINGTON— Freddie Mac, the mortgage company, releases weekly mortgage rates, 10 a.m..

  • Novartis to use Google technology for eye care Tuesday, 15 Jul 2014 | 8:09 AM ET

    Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease. Terms of the agreement between the companies were not detailed in a statement released Tuesday by Novartis.

  • ZURICH, July 15- Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus. The device for diabetics would measure glucose in tear fluid and send the data wirelessly to a mobile device, Novartis said.

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.